South Korea · Delayed Price · Currency is KRW Y-Biologics Statistics
Total Valuation
Y-Biologics has a market cap or net worth of KRW 212.34 billion. The enterprise value is 186.80 billion.
| Market Cap | 212.34B |
| Enterprise Value | 186.80B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Y-Biologics has 15.18 million shares outstanding. The number of shares has increased by 1.37% in one year.
| Current Share Class | 15.18M |
| Shares Outstanding | 15.18M |
| Shares Change (YoY) | +1.37% |
| Shares Change (QoQ) | +1.44% |
| Owned by Insiders (%) | 29.49% |
| Owned by Institutions (%) | 3.32% |
| Float | 10.63M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 76.17 |
| PB Ratio | 9.47 |
| P/TBV Ratio | 9.69 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 67.01 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 16.45, with a Debt / Equity ratio of 0.70.
| Current Ratio | 16.45 |
| Quick Ratio | 16.08 |
| Debt / Equity | 0.70 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.94 |
| Interest Coverage | -5.17 |
Financial Efficiency
Return on equity (ROE) is -221.97% and return on invested capital (ROIC) is -24.13%.
| Return on Equity (ROE) | -221.97% |
| Return on Assets (ROA) | -18.46% |
| Return on Invested Capital (ROIC) | -24.13% |
| Return on Capital Employed (ROCE) | -21.22% |
| Weighted Average Cost of Capital (WACC) | 3.85% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +45.54% in the last 52 weeks. The beta is -0.16, so Y-Biologics's price volatility has been lower than the market average.
| Beta (5Y) | -0.16 |
| 52-Week Price Change | +45.54% |
| 50-Day Moving Average | 21,351.80 |
| 200-Day Moving Average | 21,602.30 |
| Relative Strength Index (RSI) | 25.89 |
| Average Volume (20 Days) | 139,313 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Y-Biologics had revenue of KRW 2.79 billion and -44.46 billion in losses. Loss per share was -2,966.08.
| Revenue | 2.79B |
| Gross Profit | 2.19B |
| Operating Income | -10.89B |
| Pretax Income | -44.46B |
| Net Income | -44.46B |
| EBITDA | -8.92B |
| EBIT | -10.89B |
| Loss Per Share | -2,966.08 |
Balance Sheet
The company has 41.17 billion in cash and 15.63 billion in debt, with a net cash position of 25.54 billion or 1,682.76 per share.
| Cash & Cash Equivalents | 41.17B |
| Total Debt | 15.63B |
| Net Cash | 25.54B |
| Net Cash Per Share | 1,682.76 |
| Equity (Book Value) | 22.42B |
| Book Value Per Share | 1,474.60 |
| Working Capital | 39.90B |
Cash Flow
In the last 12 months, operating cash flow was -6.51 billion and capital expenditures -1.53 billion, giving a free cash flow of -8.04 billion.
| Operating Cash Flow | -6.51B |
| Capital Expenditures | -1.53B |
| Depreciation & Amortization | 1.97B |
| Net Borrowing | 34.32B |
| Free Cash Flow | -8.04B |
| FCF Per Share | -529.58 |
Margins
| Gross Margin | 78.53% |
| Operating Margin | -390.67% |
| Pretax Margin | -1,594.90% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Y-Biologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.37% |
| Shareholder Yield | -1.37% |
| Earnings Yield | -20.94% |
| FCF Yield | -3.79% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Y-Biologics has an Altman Z-Score of 0.84 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.84 |
| Piotroski F-Score | 3 |